Caribou Biosciences is stopping work on its two remaining cancer cell therapies and exploring strategic alternatives for the ...

The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...

If you have a social media account, you’ve almost certainly seen plenty of stories about scientific discoveries that are set ...

A genome search and protein language model produced new DNA-moving proteins, including one that doubled targeted insertion in lab tests.

Three exceptional scientists each received $250,000 – the largest unrestricted scientific award available to early-career scientists in ...

Caribou Biosciences is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.

When you hear the word "cancer," what kind of image comes to mind?A life-threatening disease. A disease where cells continue to multiply. A disease involving genetic abnormalities.Before I started my ...

Prioritize North America, cell therapy manufacturing and viral vectors; leverage AI, CRISPR, partnerships and scalable production to accelerate commercializationDublin, Oct. 07, 2026 (GLOBE NEWSWIRE) ...

Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more ...

The 2026 Nobel Prize for Chemistry has been awarded to Henri Kagan of Paris-Sud University and Kenso Soai of the Tokyo University of Science for their work exploring the fundamental geometry of ...

Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Global Drug Discovery Platforms Market Size, Share & Industry Analysis Report by Drug Type, End Use, Application, Therapeutic, Regional Outlook and Forecast, ...